Furthermore, through collecting the data of PSMA expression and patients’ prognosis from The Cancer Genome Atlas (TCGA) database, a Kaplan-Meier survival analysis was conducted to show that GBM patients with relatively higher PSMA expression suffered from poorer prognosis (Figure 1C). This evidence concerns the gene FOLH1 and glioblastoma.